Eloxx Pharmaceuticals Announces Open Investigational New Drug Application (IND) for Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with G542X Mutation
Professor Eitan Kerem, head of the Division of Pediatrics at the Hadassah Medical Center, will serve as the Global Lead Investigator for this clinical trial. Eloxx Pharmaceuticals, Inc. (ELOX),…
 for Phase 2 Clinical Trial of ELX-02 in Cystic Fibrosis Patients with G542X Mutation "Pinterest")
